A Phase 2, Open-Label Study Investigating the Safety and Efficacy of MDMA-Assisted Therapy for Veterans With Posttraumatic Stress Disorder (PTSD)
A Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with PTSD.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- Sunstone Medical
- Principal investigator
- Manish Agarwal
- Start date
- 2026-06-30
- End date
- 2027-08-01
- Registry ID
- NCT07569159
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.